Ribo's siRNA Drug RBD1016 for the Treatment of Chronic Hepatitis B Has Completed a Clinical Study for Safety and Pharmacokinetic Evaluation in Healthy Subjects

Ribo Life Science Co., Ltd. (Ribo) recently announced the completion of "A randomized, double-blind, placebo-controlled, single-dose escalating Phase I clinical study to evaluate the safety and pharmacokinetics of RBD1016 in healthy subjects" of its Class 1 siRNA drug for chronic hepatitis B in Australia.

Ribo was selected as one of the "50 Smartest Companies" by MIT Technology Review

On Nov. 19, MIT Technology Review unveiled its list of "50 Smartest Companies" (TR50) of 2020 in Suzhou, China. Thanks to the innovative breakthroughs in oligonucleotide therapeutics, Ribo was shortlisted as a manufacturer of innovative drugs and listed as a TR50 smart company.

Ribo obtained an implied license for clinical trials of its new drug for treatment of metastatic prostate cancer

Suzhou Ribo Life Science Co., Ltd. has recently obtained an implied license for clinical trials of its innovative ASO drug ISIS 560131, which had been introduced and developed by Ribo, following review by the Center for Drug Evaluation under the National Medical Products Administration.

Ribo raised 470 million yuan in its Series C2 financing

Suzhou Ribo Life Science Co., Ltd. announced today that 470 million yuan was raised during its Series C2 financing. In this round of financing, the lead investors included China Venture Capital Fund Corporation Ltd., CICC Qide Fund, and GL Ventures, and the co-investors included renowned investment institutes such as Hengxu Capital, Everest VC, Sinopharm-CICC Capital, Shenzhen Co-way Capital Services Co., Ltd., Shanghai Free Trade Zone Equity Fund Management Co., Ltd., and Hongtao Capital

Ribo raised 200 million yuan in its Series C1 financing

On December 5, 2019, Suzhou Ribo Life Science Co. Ltd., announced the successful completion of Series C1 financing worth RMB 203 million.